In 1867 the Viennese surgeon Theodor Billroth claimed that cancer could be cured with the knife 1 , but later review of his own results showed that this was seldom true. Even today, despite advances in surgery, radiotherapy and chemotherapy over the past century, cancer is an increasing cause of morbidity and mortality in most countries. In some, it has now overtaken heart disease as the commonest cause of death 2 .
Although the increased funding for cancer research during the past 25 years has had negligible impact on cancer mortality rates, it has immensely increased our knowledge of the mechanisms whereby normal cells and tissues become malignant 3 . Pharmacological intervention to arrest or reverse such mechanisms is termed chemoprevention, and is well established in the prevention of other diseases such as dental caries, heart attacks and stroke. In this review I discuss the promising results already achieved in the chemoprevention of epithelial neoplasia, citing breast and colorectal cancers as examples. There already exists a case for establishing prevention clinics, run by oncologists in collaboration with clinical geneticists and molecular epidemiologists, to assess and advise individuals at high risk of developing certain wellcharacterized malignancies. Dietary intervention 4 will not be considered.
PRINCIPLES OF CANCER CHEMOPREVENTION
Cancer chemoprevention is the inhibition, retardation or reversal of carcinogenic processes by chemical means, and includes the treatment of patients who have undergone successful treatment of a primary malignancy but are at increased risk of a second 5 . This latter concept is designated tertiary' chemoprevention 6 . The prevention of carcinogenesis at a premalignant stage is`primary', and prevention at an early phase of malignancy is`secondary'.
Several effective chemopreventive agents were ®rst developed for adjuvant chemotherapy; the preventive action of tamoxifen, for example, emerged when it was found to decrease breast tumours in the contralateral breast after surgery 7 . Such overlap between chemotherapeutic and chemopreventive properties implies an opportunity to conduct pilot studies of new chemopreventive agents in patients who already have cancer, and this has been done with the putative agents piroxicam 8 , di¯uoromethylornithine (DFMO) 9 , and perillyl alcohol 10 .
Although the development of malignancy is the result of a complex interaction between genetic and environmental in¯uences, the multistep model of carcinogenesis 11 has provided a structure into which ®ndings can be incorporated. Existing paradigms include clonal evolution 12 and epigenetic changes 4 , and these too offer pointers to targets for chemopreventive agents. In colorectal neoplasia, carcinogenesis has been characterized in exceptional detail ( Figure 1 ).
TAMOXIFEN CONTROVERSY
Opinions differ between America and Europe on the chemopreventive ef®cacy of two antioestrogenic agents, tamoxifen and raloxifene. The BCPT study in the United States involved 13 388 women at relatively high risk but free of detectable invasive breast cancer at study recruitment 13 . Tamoxifen whole by 45%, and also seemed to prevent the progression of established preneoplastic lesions of the breast. These results led the US Food and Drug Administration to approve the use of tamoxifen 20 mg/day in women deemed at increased risk of breast cancer, albeit with consideration of its toxicities. Similar reductions in breast cancer were seen in a trial of raloxifene for postmenopausal osteoporosis; in this instance the women were not thought to be at excess risk of breast cancer 14 .
By contrast, two smaller European trials of tamoxifen in healthy women not judged at high risk have not shown any protective effect 15, 16 . In Europe, the International Breast Cancer Intervention study has now recruited more than 4000 women with at least a two-fold increased risk of developing breast cancer, and the results are awaited. Presumably the transatlantic differences of opinion on the preventive value of agents such as tamoxifen re¯ect differences in the study populations.
AVOIDANCE OF TOXICITY
In ancient times both Hippocrates and Galen warned that treatment for hidden cancer could hasten death 1 . Their wisdom was borne out in large-scale chemoprevention trials that may have increased cancer incidence in subsets of the population 17, 18 . These negative results not only highlight the importance of gaining a detailed mechanistic understanding of putative chemopreventive agents before administering them to large groups who do not have cancer, but also emphasize the need to weigh up toxicity against bene®t.
For example, although the vitamin A analogues isotretinoin 19 and retinol palmitate 20 have been shown to prevent second primary cancers in patients with malignancies of the lung and head and neck, the toxic effects are such that many patients stop taking them. Similarly the synthetic retinoid fenretinide decreased the risk of breast cancer in premenopausal women in a tertiary chemoprevention study, but night blindness and erythema proved prohibitive with high doses 21 . Some newer retinoids that selectively bind the three retinoid X receptors may lack these drawbacks; they appear highly chemopreventive in preclinical mammary models but do not possess the toxicity/teratogenicity pro®le of typical retinoids 22 .
IS ASPIRIN THE ULTIMATE CHEMOPREVENTIVE?
In families with familial adenomatous polyposis (FAP), the presence of the APC gene defect confers a 100% lifetime risk of colorectal cancer 23 . At present affected individuals are advised to undergo regular colonoscopy, with or without eventual colectomy 24 . For many years nonsteroidal anti-in¯ammatory drugs such as aspirin and sulindac have been known to promote regression of such polyps, and interest has focused on their ability to inhibit the cyclo-oxygenase (COX) enzyme involved in prostaglandin synthesis. The COX enzyme consists of two isoforms, and irreversible inhibition of COX1 by aspirin is thought to account predominantly for the drug's gastrointestinal toxicity. Highly selective inhibitors of COX2 have therefore been developed, such as celecoxib. This anti-in¯ammatory drug was recently approved by the US Food and Drug Administration as an adjunct to usual care in FAP, on the basis of an unpublished clinical trial in 83 patients showing 28% fewer polyps in those receiving celecoxib, 400 mg twice daily for six months, than in the placebo group 25 .
Inherited predisposition accounts for only a small proportion of colorectal cancers: more than 80% are sporadic 23 . The most convincing epidemiological evidence for decreased incidence of total colorectal cancer as a result of pharmacological intervention exists for aspirin. Retrospective epidemiological studies suggest a decrease of up to 50% in regular aspirin users 26, 27 , although there may be a delay of a decade or so before bene®t 28 . There are hopes that natural polyphenols such as turmeric extracts 29 and newer selective COX2 inhibitors 25 will offer similar chemopreventive ef®cacy with less toxicity.
The development of aspirin as a cancer chemopreventive agent raises the issue of indirect biomarkers for ef®cacy, analogous to sphygmomanometry or blood cholesterol measurement in cardiovascular disease. As judged by`preneoplastic biomarkers' such as colon epithelial prostaglandins (Table 1) 30 . Biomarkers such as gluthathione S-transferase activity, relevant to the effects of many chemopreventive agents including aspirin 31 , may be measurable as a simple blood test indicating events in the colon 32 . Finally, genetic`risk biomarkers' may also prove important in selection of individuals for large-scale chemoprevention trials 33 .
CONCLUSION
Effective agents have already been identi®ed in the brief history of cancer chemoprevention. Retinoids, tamoxifen and raloxifene have entered clinical practice in the prevention of epithelial malignancies. Aspirin, highly selective COX2 inhibitors, and certain natural compounds offer promise in preventing colorectal cancer. The success of future chemoprevention trials will depend on selection of suitable individuals, use of sensitive biomarkers and avoidance of toxicity.
